Stanford L Peng

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 2

Top Topics

Top Venues

Science translational medicine

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Mark F Maurer, Katherine E Lewis, Joseph L Kuijper, Dan Ardourel, Chelsea J Gudgeon, Siddarth Chandrasekaran, Sherri L Mudri, Kayla N Kleist, Chris Navas, Martin F Wolfson, Mark W Rixon, Ryan Swanson, Stacey R Dillon, Steven D Levin, Yengo Raymond Kimbung, Masato Akutsu, Derek T Logan, Björn Walse, Kristine M Swiderek, Stanford L Peng
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity. Nature communications 13 (1) (2022)
Djamilatou Adom, Stacey R Dillon, Jinfeng Yang, Hao Liu, Abdulraouf Ramadan, Kushi Kushekhar, Samantha Hund, Amanda Albright, Maykala Kirksey, Titilayo Adeniyan, Katherine E Lewis, Lawrence Evans, Rebecca Wu, Steven D Levin, Sherri Mudri, Jing Yang, Erika Rickel, Michelle Seaberg, Katherine Henderson, Chelsea J Gudgeon, Martin F Wolfson, Ryan M Swanson, Kristine M Swiderek, Stanford L Peng, Keli L Hippen, Bruce R Blazar, Sophie Paczesny
ICOSL+ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist. Science translational medicine 12 (564) (2021)